厄贝沙坦治疗原发性高血压并早期肾损伤的临床疗效

Clinical effect of irbesartan in treating essential hypertension with early renal damage

目的探讨厄贝沙坦治疗原发性高血压并早期肾损伤的临床疗效。方法选取广汉市第二人民医院2014年9月—2016年3月收治的原发性高血压并早期肾损伤患者70例,按照治疗方案不同将患者分为观察组与对照组,各35例。观察组予以厄贝沙坦治疗,对照组予以美托洛尔治疗,均持续治疗8周。比较两组患者治疗前后血压与尿微量蛋白(MAU)水平、肱动脉舒张功能。结果治疗前后两组患者收缩压、舒张压比较,差异无统计学意义(P>0.05)。治疗前两组患者MAU水平比较,差异无统计学意义(P>0.05);治疗后观察组MAU水平低于对照组(P<0.05)。治疗前两组患者反应性充血时、含硝酸甘油后内径舒张比较,差异无统计学意义(P>0.05);治疗后观察组患者反应性充血时内径舒张大于对照组(P<0.05);治疗后两组患者含硝酸甘油后内径舒张比较,差异无统计学意义(P>0.05)。结论厄贝沙坦治疗原发性高血压并早期肾损伤的临床疗效确切,可改善患者肾小球功能,降低血压,提高患者的生活质量。

Objective To investigate the clinical effect of irbesartan in treating essential hypertension with early renal damage. Methods A total of 70 cases of essential hypertension with early renal damage patients were selected from September2014 to March 2016 in the Second People＇s Hospital of Guanghan,which were divided into observation group and control group according to different treatments,35 cases in each group. Observation group was treated with irbesartan,control group was used metoprolol for treatment,both groups were treated for 8 weeks. The blood pressure and MAU,brachial artery diastolic function before and after treatment were compared between the two groups. Results Before and after treatment,no statistically significant differences of systemic blood pressure or diastolic blood pressure was found between the two groups（ P〉0. 05）. Before treatment,no statistically significant difference of MAU level was found between the two groups（ P〉0. 05）; after treatment,the MAU level of observation group was lower than control group（ P〈0. 05）. Before treatment,no statistically significant differences of diameter percentage at time of reactive hyperemia or oral nitroglycerin was found between the two groups（ P〉0. 05）; after treatment,diameter percentage of observation group was higher than control group at time of reactive hyperemia（ P〈0. 05）,no statistically significant difference of diameter percentage at time of oral nitroglycerin was found between the two groups（ P〉0. 05）. Conclusion Irbesartan has an obviously clinical effect in treating essential hypertension with early renal damage,it can improve the glomerular function,lower blood pressure and improve the quality of patients＇ life.